Industry
Metabolon and the Oxford Parkinson's Disease Centre will identify new metabolomic biomarkers to advance Parkinson's research and detect new therapeutic targets
Simone Guglielmetti (University of Milan) discusses the use of inactivated microbes as alternative to live probiotics.
The partnership program aims to develop next-generation probiotics and therapeutics to modulate the gut microbiota to target areas like anxiety, depression and mental well-being.
It's the second agreement between Boehringer Ingelheim and BiomX focused on IBD. The first one in 2020.
Locus is developing a new class of precision engineered bacteriophage treatments for a diverse set of bacterial diseases.
New publication reveals how a keystone strain exerts potential to impact a spectrum of health outcomes through immune and metabolic regulation.
Industry
Sponsored by
SynBalance® ProBeautyShield has been selected as the ingredient of the year in beauty from within category.
The collaboration with ADM a premier global human and animal nutrition company will combine cutting-edge technologies to the pipeline of microbiome-focused innovation from Gnubiotics.
The solutions will aim to improve the diagnosis of diseases thanks to a more detailed analysis of the intestinal, oral, ocular, cancer or pulmonary microbiomes.
Patrice Cani (Université catholique de Louvain) discusses the future of Akkermansia municiphila.
